Skip to content
All news
ProductLaunch

Tandem Diabetes Care Expands Insulin Pump Support for Libre 3 Plus in Europe

Tandem Diabetes Care (TNDM) announced expanded connectivity of its t:slim X2 insulin pump with Abbott's FreeStyle Libre 3 Plus CGM in five European countries. The news comes as TNDM shares have fallen 28.49% year-to-date.

July 11, 2026
2 min read
Source: Simply Wall St.
Share:

Key Numbers

share price
$15.41
ytd change
-28.49%
one year return
-1.15%

Tandem Diabetes Care (TNDM) announced that its t:slim X2 insulin pump with Control-IQ+ technology now integrates with Abbott's (ABT) FreeStyle Libre 3 Plus continuous glucose monitor (CGM) across five European countries. The expansion follows a 28.49% year-to-date decline in TNDM shares to $15.41, raising questions about valuation.

The Product

The t:slim X2 with Control-IQ+ is a hybrid closed-loop system that automatically adjusts insulin delivery based on CGM readings. Connectivity with Libre 3 Plus offers users improved accuracy and eliminates fingerstick calibration.

Pricing and Availability

Tandem has not disclosed specific pricing for the new European markets. The system is currently available in Germany, France, Italy, Spain, and the Netherlands, with plans for further expansion.

Competition

Tandem faces competition from Medtronic and Insulet (Omnipod), as well as CGM systems from Dexcom. The Abbott partnership strengthens its position in the growing CGM market.

Potential Impact on the Company

This expansion could boost Tandem's European market share and revenue, though the stock has yet to react positively. The financial impact will depend on adoption rates and competitive dynamics.

Frequently Asked Questions

The expansion covers five countries: Germany, France, Italy, Spain, and the Netherlands.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.